Business Context and Reporting Period
Inmune Bio, Inc. (INMB) filed a Form 8-K Current Report on June 30, 2026, regarding a material definitive agreement. The company is incorporated in Nevada and its principal executive offices are located in Boca Raton, Florida.
Key Financial Metrics
This filing does not report standard operating metrics such as revenue, profit, cash flow, or margins. The primary financial data relates to a specific capital transaction:
- Expected Proceeds: The Company expects to receive an aggregate of $905,957 from the exercise of warrants.
- Shares Issued: 647,112 shares of common stock will be issued upon exercise.
- Exercise Price: The reduced exercise price is $1.40 per share (reduced from $1.95).
- Warrant Volume: The transaction covers 50% of the "April 2024 Warrants" held by participating holders.
Material Changes
The filing details a warrant inducement offer and amendment affecting the April 2024 Warrants:
- Price Reduction: The exercise price for 50% of the warrants was reduced from $1.95 to $1.40 to induce immediate exercise.
- Maturity Extension: The maturity date for the remaining 50% of the warrants (those not exercised) was extended from June 30, 2026, to December 31, 2027.
- Capital Raise: The company secured immediate cash inflow of approximately $0.9 million through the partial exercise of existing warrants.
Outlook, Risks, and Management Commentary
Management executed this transaction to secure liquidity and extend the life of remaining warrant obligations. The shares underlying the warrants are registered under an effective registration statement (File No. 333-279036), allowing for immediate resale upon exercise. The filing does not provide specific forward-looking guidance on clinical trials, product development, or future financial performance beyond the terms of this agreement.
Investor Verification Checklist
- Verify the total number of April 2024 Warrants outstanding to assess the dilution impact of the 647,112 shares issued.
- Confirm the current market price of INMB stock relative to the $1.40 reduced exercise price to evaluate the incentive for holders.
- Review the company's cash position post-transaction to determine runway extension.
- Check the status of the remaining 50% of warrants now maturing in December 2027.